{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:47:31Z","timestamp":1775846851705,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jns.2017.03.025","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:16:35Z","timestamp":1489709795000},"page":"129-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Apraclonidine in the treatment of ptosis"],"prefix":"10.1016","volume":"376","author":[{"given":"Subhashie","family":"Wijemanne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanya","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.03.025_bb0005","first-page":"951","article-title":"Ocular effects of apraclonidine in Horner syndrome","volume":"118","author":"Morales","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2017.03.025_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.wno.0000172602.10008.18","article-title":"Are we ready to replace cocaine with apraclonidine in the pharmacologic diagnosis of Horner syndrome?","volume":"25","author":"Kardon","year":"2005","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2017.03.025_bb0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archopht.121.8.1201","article-title":"The utility of 0.5% apraclonidine in the diagnosis of horner syndrome","volume":"121","author":"Brown","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2017.03.025_bb0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/IOP.0b013e31817f526a","article-title":"Use of 0.5% apraclonidine solution in evaluation of blepharoptosis","volume":"24","author":"Yazici","year":"2008","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.jns.2017.03.025_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D306G8W0MC","article-title":"The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face","volume":"11","author":"Scheinfeld","year":"2005","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.jns.2017.03.025_bb0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00002341-199903000-00005","article-title":"Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid","volume":"15","author":"Esmaeli-Gutstein","year":"1999","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.jns.2017.03.025_bb0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.iop.0000196322.05586.6a","article-title":"Effect of 0.5% apraclonidine on ptosis in Horner syndrome","volume":"22","author":"Garibaldi","year":"2006","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.jns.2017.03.025_bb0040","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up","volume":"90","author":"Ramirez-Castaneda","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2017.03.025_bb0045","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2017.03.025_bb0050","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.03.025_bb0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1526-4637.2005.05029.x","article-title":"Treatment of ptosis as a complication of botulinum toxin injection","volume":"6","author":"Omoigui","year":"2005","journal-title":"Pain Med."},{"key":"10.1016\/j.jns.2017.03.025_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00702-007-0768-7","article-title":"Botulinum toxin in the treatment of blepharospasm and hemifacial spasm","volume":"115","author":"Kenney","year":"2008","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.jns.2017.03.025_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.3.6.9","article-title":"A prototype external magnetic eyelid device for Blepharoptosis","volume":"3","author":"Houston","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jns.2017.03.025_bb0070","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00006534-200010000-00046","article-title":"Eyelid crutches for ptosis: a forgotten solution","volume":"106","author":"Lapid","year":"2000","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.jns.2017.03.025_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/OPTH.S76054","article-title":"Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure","volume":"9","author":"Akkaya","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jns.2017.03.025_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2016.11.029","article-title":"Treatment of blepharospasm with apraclonidine","volume":"372","author":"Vijayakumar","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2017.03.025_bb0085","first-page":"284","article-title":"Horner's syndrome, an American discovery","volume":"25","author":"Kisch","year":"1951","journal-title":"Bull. Hist. Med."},{"key":"10.1016\/j.jns.2017.03.025_bb0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/bjo.79.12.1098","article-title":"Long term effect of apraclonidine","volume":"79","author":"Araujo","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jns.2017.03.025_bb0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archopht.1995.01100030041019","article-title":"The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group","volume":"113","author":"Stewart","year":"1995","journal-title":"Arch. Ophthalmol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17301946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17301946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:41:42Z","timestamp":1692726102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17301946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":19,"alternative-id":["S0022510X17301946"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.03.025","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apraclonidine in the treatment of ptosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}